Virologic and regimen termination surrogate end points in AIDS clinical trials.
about
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trialLong-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era.Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study.Incorporating durability information in the comparison of proportions of patients with HIV suppression.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).
P2860
Q34103495-549A3289-7BC5-45F5-896D-7B1A45162616Q34176854-C77DE750-D5FB-49D5-BB3D-BAFA6665BA07Q37692734-F916C987-8191-4C49-9A16-A8D7E542129EQ38759954-D6254EC1-500F-4622-8CF1-3CFF633D5D8AQ43820683-39217ACD-B255-4249-9219-35336D6489A7Q44224686-F05CD1D9-1799-46F4-9BC7-802834E8D009Q46636395-90EBFCDD-5C2B-41BD-B084-C4E0A1FA797EQ50487955-B0C59B92-9688-4FBE-A2D1-DF4582381CF1Q53851252-46851726-5CD0-43D3-9756-A4C5CE792BAD
P2860
Virologic and regimen termination surrogate end points in AIDS clinical trials.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Virologic and regimen termination surrogate end points in AIDS clinical trials.
@en
type
label
Virologic and regimen termination surrogate end points in AIDS clinical trials.
@en
prefLabel
Virologic and regimen termination surrogate end points in AIDS clinical trials.
@en
P2093
P356
P1476
Virologic and regimen termination surrogate end points in AIDS clinical trials.
@en
P2093
D R Kuritzkes
P B Gilbert
S M Hammer
V DeGruttola
P304
P356
10.1001/JAMA.285.6.777
P407
P577
2001-02-01T00:00:00Z